$1.170
-0.029 (-2.50%)At close
- High
- 1.280
- Open
- 1.220
- VWAP
- 1.16
- Vol
- 2.77M
- Mkt Cap
- 24.63M
- Low
- 1.030
- Amount
- 3.21M
- EV/EBITDA, TTM
- -0.51
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology.
Analyst Ratings (1)
Maxim
—
2025-07-23
Maxim
2025-07-23
Price Target
—
Maxim Group
$2
2024-07-11
Maxim Group
2024-07-11
Price Target
$2
Maxim Group
—
2023-09-28
Maxim Group
2023-09-28
Price Target
—
Maxim Group
$10
2023-03-31
Maxim Group
2023-03-31
Price Target
$10
Maxim Group
—
2021-02-05
Maxim Group
2021-02-05
Price Target
—
Valuation Metrics
Events Timeline
News
1.008-24PRnewswireBrainStorm to Participate in Dubai International Pharmaceuticals Conference
9.508-14PRnewswireBrainStorm Reports Q2 2026 Financial Results and Corporate Update
9.508-14Yahoo FinanceBrainStorm Cell Therapeutics Reports Q2 2026 Financial Results and Corporate Update
8.505-28PRnewswireFormer FDA Official Joins BrainStorm Board Ahead of Historic ALS Trial
9.505-15seekingalphaBrainStorm Cell Therapeutics Q1 Earnings Beat Expectations
BCLI FAQ — answered by Alphio AI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease; progressive multiple sclerosis (PMS); Alzheimer’s disease (AD); and other neurodegenerative diseases. Its NurOwn, a cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived MSCs to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. It has completed a Phase III pivotal trial in ALS (NCT03280056); this trial investigated the safety and efficacy of repeat-administration of autologous MSC-NTF cells. The Company's wholly owned subsidiary, Brainstorm Cell Therapeutics Ltd. holds exclusive rights to commercialize NurOwn technology. It operates in the Healthcare sector (BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES) industry).
1 analysts cover BCLI: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 6.00.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.